热门资讯> 正文

CorMetrics在公布第三季度业绩后上涨

2026-08-13 19:34

CorMedix press release (CRMD): Q2 GAAP EPS of $0.29 beats by $0.05.
Revenue of $101.93M (+156.5% Y/Y) beats by $5.88M.
The Company maintains full-year 2026 consolidated revenue guidance of $325 to $345 million vs $334.57M consensus, and raises full-year adjusted EBITDA guidance to a range of $125 to $140 million. Cash OpEx guidance is narrowed to a range of $145 to $155 million.
Shares +5% PM.

More on CorMedix

CorMedix: Bleak Short-Term Outlook, But Significantly Undervalued For The Long Run
CorMedix: Long-Term Prospects Remain Poor Despite Q1 Beat
CorMedix Q2 Earnings Preview
These 10 small-cap U.S. healthcare companies rank among the market's most attractively valued stocks
Seeking Alpha’s Quant Rating on CorMedix

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。